• Request for Information (RFI): Invitation to Comment on Inclusion in Clinical Research Across the Lifespan (NOT-OD-17-059)
  National Institutes of Health
• Notice of Clarification of Application Due Dates for RFA-OD-17-004 "Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U01) " (NOT-OD-17-060)
  Office of Behavioral and Social Science Research
• Notice of Clarification of Application Due Dates for RFA-OD-17-005 "Intensive Longitudinal Analysis of Health Behaviors: Leveraging New Technologies to Understand Health Behaviors (U24)" (NOT-OD-17-061)
  Office of Behavioral and Social Science Research, National Cancer Institute, National Institute on Drug Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, National Institute on Drug Abuse
  National Institute of Mental Health
• New "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018 (NOT-OD-17-062)
  National Institutes of Health
• Notice of Correction to Instructions for Application Submission for PAR-17-237 "Centers for AIDS Research (P30)" (NOT-AI-17-024)
  National Institute of Allergy and Infectious Diseases
• Notice of Correction to Instructions for Application Submission for PAR-17-238 "Developmental Centers for AIDS Research (P30)"
  (NOT-AI-17-025)
  National Institute of Allergy and Infectious Diseases
• Notice of Change to Budget Instructions for PAR-15-332 "Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01)"
  (NOT-CA-17-051)
  National Cancer Institute
• Notice of Change to Budget Instructions for PAR-15-333, "Sustained Support for Informatics Resources for Cancer Research and Management (U24)"
  (NOT-CA-17-052)
  National Cancer Institute
• Presolicitation Notice: Request for Proposals (RFP) N01PC65003-74 "Surveillance, Epidemiology, and End Results (SEER) Program"
  (NOT-CA-17-053)
  National Cancer Institute
• Notice of NIDA's Participation in PAR-17-234 "Mechanisms and Consequences of Sleep Disparities in the U.S. (R01)"
  (NOT-DA-17-027)
  National Institute on Drug Abuse
• Notice of NIDA's Participation in PAR-17-235 "Mechanisms and Consequences of Sleep Disparities in the U.S. (R21)"
  (NOT-DA-17-028)
  National Institute on Drug Abuse
• Advancing Conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS) (U18)
  (NOT-FD-17-009)
  Food and Drug Administration
• Notice of Modifications to Eligibility for PAR-16-415 "Centers of Biomedical Research Excellence Program (COBRE)(P20)"
  (NOT-GM-17-005)
  National Institute of General Medical Sciences
• Notice of Intent to Publish a Funding Opportunity Announcement for Implementation Research for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)
  (NOT-HL-17-493)
  National Heart, Lung, and Blood Institute
• Notice of Intent to Publish a Funding Opportunity Announcement to Increase Use of Cardiac and Pulmonary Rehabilitation in Traditional and Community Settings (R61/R33)
  (NOT-HL-17-495)
  National Heart, Lung, and Blood Institute
• Notice of NHLBI Participation in PA-16-169 Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development (R01)
  (NOT-HL-17-509)
  National Heart, Lung, and Blood Institute
• Notice of Change to Key Dates for PAR-16-021 "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)"
  (NOT-HL-17-510)
  National Heart, Lung, and Blood Institute
• Reminder To AHRQ Grantees Whose Existing Non-Competing Grants Were Converted From Pooled Accounts To Subaccounts In FY2015 - Drawing Funds From PMS  
(NOT-HS-17-013)  
Agency for Healthcare Research and Quality  
• Expiring Funds Alert to AHRQ Grant Recipients who Received Multi-Year Funded Awards  
(NOT-HS-17-014)  
Agency for Healthcare Research and Quality  
• New AHRQ "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018  
(NOT-HS-17-015)  
Agency for Healthcare Research and Quality  
• Notice of Correction to Advisory Council Review Dates for PAR-17-159 "Data Science Research: Personal Health Libraries for Consumers and Patients (R01)"  
(NOT-LM-17-005)  
National Library of Medicine  
• Notice of Change in the Expiration Date for PA-14-112 "A Family-Centered Self-Management of Chronic Conditions (R01)"  
(NOT-NR-17-002)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-113 "A Family-Centered Self-Management of Chronic Conditions (R21)"  
(NOT-NR-17-003)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-140 "Community Partnerships to Advance Research (CPAR) (R15)"  
(NOT-NR-17-004)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-141 "Community Partnerships to Advance Research (CPAR) (R21)"  
(NOT-NR-17-005)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-142 "Community Partnerships to Advance Research (CPAR) (R01)"  
(NOT-NR-17-006)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-176 "Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21)"  
(NOT-NR-17-007)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-177 "Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01)"  
(NOT-NR-17-008)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-180 "mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01)"  
(NOT-NR-17-009)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-181 "mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21)"  
(NOT-NR-17-010)  
National Institute of Nursing Research  
• Notice of Change in the Expiration Date for PA-14-316 "Obesity and Asthma: Awareness and Self-Management (R01)"  
(NOT-NR-17-011)  
National Institute of Nursing Research  
• Extension of Expiration Date for PAR-15-070 "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)"  
(NOT-NS-17-020)  
National Institute of Neurological Disorders and Stroke  
• Extension of Expiration Date for PAR-15-071 "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)"  
(NOT-NS-17-021)  
National Institute of Neurological Disorders and Stroke  
• Extension of Expiration Date for RFA NS-16-013 "Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)"  
(NOT-NS-17-022)  
National Institute of Neurological Disorders and Stroke  
• Notice of Intent to Publish a Funding Opportunity Announcement for Translational Neural Devices Program (U44)  
(NOT-NS-17-023)  
National Institute of Neurological Disorders and Stroke  
• Notice of Intent to Publish a Funding Opportunity Announcement for Translational Neural Devices Program (UG3/UH3)  
(NOT-NS-17-024)  
National Institute of Neurological Disorders and Stroke
• Notice to Extend the Expiration Date for PA-14-069 "Neurobiology of Migraine (R21)"
  (NOT-NS-17-026)
  National Institute of Neurological Disorders and Stroke
• Notice to Extend the Expiration Date for PA-14-068 "Neurobiology of Migraine (R01)"
  (NOT-NS-17-027)
  National Institute of Neurological Disorders and Stroke
• Notice of Change in Award Project Period for RFA-RM-17-010 "Limited Competition - Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)"
  (NOT-RM-17-024)
  NIH Roadmap Initiatives
• Notice of Change in Award Budget for RFA-AA-17-016 "Alcohol-PTSD Comorbidity: Preclinical Studies of Models and Mechanisms (R01)"
  (NOT-AA-17-003)
  National Institute on Alcohol Abuse and Alcoholism
• Revision of NOT-AI-04-035, NIAID Primary Caregiver Technical Assistance Supplements Notice
  (NOT-AI-17-011)
  National Institute of Allergy and Infectious Diseases
• Notice of Change in PAR-17-149 "Phased Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R61/R33)"
  (NOT-AT-17-007)
  National Center for Complementary and Integrative Health
• Notice of Change in PAR-17-162 "Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33)"
  (NOT-AT-17-008)
  National Center for Complementary and Integrative Health
• Notice of Change to Budget Instructions for PAR-15-331 "Advanced Development of Informatics Technologies for Cancer Research and Management (U24)"
  (NOT-CA-17-050)
  National Cancer Institute
• Notice of Change in the Expiration Date for PAR-14-004 "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03)"
  (NOT-DA-17-024)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PAR-14-105 "Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21)"
  (NOT-DA-17-025)
  National Institute on Drug Abuse
• Notice of Change in the Expiration Date for PAR-14-106 "Synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01)"
  (NOT-DA-17-026)
  National Institute on Drug Abuse
• Notice of Correction to RFA-DA-18-005 "Expanding Medication Assisted Treatment for Opioid Use Disorders in the Context of the SAMHSA Opioid STR Grants (R21/R33)"
  (NOT-DA-17-029)
  National Institute on Drug Abuse
• Notice of Change to RFA-HL-16-025 "NHLBI Emerging Investigator Award (EIA) (R35)"
  (NOT-HL-17-488)
  National Heart, Lung, and Blood Institute
• Notice of Change to RFA-HL-16-024 "NHLBI Outstanding Investigator Award (OIA) (R35)"
  (NOT-HL-17-489)
  National Heart, Lung, and Blood Institute
• Notice of NHLBI Participation in PA-16-167 Diet and Physical Activity Assessment Methodology (R01)
  (NOT-HL-17-508)
  National Heart, Lung, and Blood Institute
• Notice of Participation in PA-17-164 "Aging Biology Research to Address Health Disparities (Admin Supp)"
  (NOT-MD-17-002)
  National Institute on Minority Health and Health Disparities

REQUEST FOR APPLICATIONS

• TITLE: NIH Director's Pioneer Award Program (DP1)
  (RFA-RM-17-005)
  SPONSOR: NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination
  Synopsis: The NIH Director’s Pioneer Award complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges that have the potential to produce an unusually high impact on enhancing health, lengthening life, and reducing illness and disability. To be considered pioneering, the proposed
research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
Application Receipt Date(s): September 1, 2017

• TITLE: NIH Director’s New Innovator Award Program (DP2)
  (RFA-RM-17-006)
  SPONSOR: NIH Roadmap Initiatives
  Synopsis: The NIH Director’s New Innovator Award (DP2) supports a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The NIH Director’s New Innovator Award complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Director’s New Innovator Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
  Application Receipt Date(s): September 8, 2017

• TITLE: NIH Director’s Transformative Research Awards (R01)
  (RFA-RM-17-007)
  SPONSOR: NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination
  Synopsis: The NIH Director’s Transformative Research Award complements NIH’s traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research. The NIH Director’s Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
  Application Receipt Date(s): September 15, 2017

• TITLE: NIH Director’s Early Independence Awards (DP5)
  (RFA-RM-17-008)
  SPONSOR: NIH Roadmap Initiatives
  Synopsis: The NIH Director’s Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.
  Application Receipt Date(s): September 22, 2017

PROGRAM ANNOUNCEMENTS

• TITLE: NICHD Exploratory/Developmental Research Grant (R21)
  (PA-17-259)
  SPONSOR: Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Scaling Established Clinical Decision Support to Facilitate the Dissemination and Implementation of Evidence-Based Research Findings (R18)
  (PA-17-260)
  SPONSOR: Agency for Healthcare Research and Quality
  Synopsis: This Funding Opportunity Announcement (FOA) invites R18 grant applications for research projects to scale and spread existing clinical decision support (CDS) to facilitate the dissemination and implementation of evidence-based research findings into clinical practice. The purposes of this FOA are to extend the implementation ("scale") and evaluation of well-established and effective CDS beyond the initial clinical setting or institution in which the CDS was originally developed and implemented, thereby extending the impact on clinical practice.
  Application Receipt/Submission Date(s): Multiple dates, see announcement

• TITLE: Developing New Clinical Decision Support to Disseminate and Implement Evidence-Based Research Findings (R18)
  (PA-17-261)
  SPONSOR: Agency for Healthcare Research and Quality
  Synopsis: This Funding Opportunity Announcement (FOA) invites R18 grant applications for developing new clinical decision support (CDS) to facilitate the dissemination and implementation of evidence-based research findings. The purposes of this FOA are to develop new, reliable, valid, and usable CDS from evidence-based research findings and then demonstrate its effectiveness to improve care in clinical practice.
  Application Receipt/Submission Date(s): Multiple dates, see announcement
OTHER FUNDING OPPORTUNITIES
(Sponsors in bold are NIH Peer Reviewed Organizations)

• TITLE: Grants
  http://www.waxmancancer.org/What-We-Do/Grants
  SPONSOR: Samuel Waxman Cancer Research Foundation (SWCRF)

• TITLE: Psychosocial Grant Program: Psychosocial Family Impact Grants
  https://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
  SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
  Synopsis: The Psychosocial: Family Impact Grants will support studies by established investigators that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. These grants are designed to fund researchers who have novel approaches to understanding the psychosocial aspects of pediatric cancer whose proposals will have clinically significant impact.

• TITLE: Psychosocial Grant Program: Psychosocial Launch Grants
  http://www.alexslemonade.org/grants/program-areas/quality-life-and-care#program-141
  SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
  Synopsis: The Psychosocial: Launch Grants will support studies by early career researchers that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. Demonstration of outstanding mentorship and a career plan that shows commitment to pediatric cancer investigation are important components of a successful application.

• TITLE: Senior Investigator Grant
  http://towercancer.org/research-grant-senior-investigator/
  SPONSOR: Tower Cancer Research Foundation

• TITLE: Edgar Gentilli Prize
  SPONSOR: Royal College of Obstetricians and Gynaecologists (RCOG)

• TITLE: SWOG Early Exploration and Development (SEED) Fund
  SPONSOR: The Hope Foundation

• TITLE: Familial RUNX1 Grant Program: Familial RUNX1 Research Grant
  http://www.alexslemonade.org/grants/runx1
  SPONSOR: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)
  Synopsis: Alex's Lemonade Stand Foundation (ALSF) is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. The Babich Family Foundation is dedicated to advancing areas of research of particular importance to families affected by familial platelet disorders (FPDs) leading to acute myeloblastic leukemia (AML) due to germline RUNX1 mutations with the ultimate goal of developing effective therapies to prevent the onset of AML. ALSF and The Babich Family Foundation have partnered to raise awareness and accelerate research around familial RUNX1 disorders. Purpose of the grant is to fund research that will develop strategies leading to the development of therapies for the prevention of the transition from pre-leukemia to leukemia for patients with the familial RUNX1 disorder. Projects should focus on familial RUNX1 disorder rather than acquired RUNX1 mutations seen during the evolution of AML.
  Research Directions of Interest:
  - Studies that develop our understanding of the biological basis for disease progression in individuals carrying familial RUNX1 mutations.
  - Studies to develop potential therapies to limit disease progression from individuals with the familial RUNX1 deficiency.
  - Development of in vitro and in vivo model systems (including but not limited to human cell, mouse or zebrafish) that: increase our understanding of disease pathogenesis, test mechanistic hypotheses, or that provide a suitable evaluation platform for the discovery of potential therapies.
  The grant is designed as seed funding for researchers with a novel scientific approach to investigating hereditary or germline RUNX1 disorder. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator's prior research, but for which a strong case can be made for the potential impact on familial RUNX1 disorder.

• TITLE: Medical Research: Heart Disease, Cancer and AIDS Research
  http://www.wwsmithcharitabletrust.org/medical.html
  SPONSOR: Smith Charitable Trust, W.W.

• TITLE: Medical Research
  http://www.greatermilwaukeefoundation.org/grants/grant-seekers/other-grant-opportunities/medical-research/
  SPONSOR: Greater Milwaukee Foundation

• TITLE: Investigator Sponsored Research (ISR)
  https://www.gilead.com/research/investigator-sponsored
  SPONSOR: Gilead Sciences, Inc. / Gilead Sciences Pty Ltd
TITLE: End-of-Life Care Nursing Career Development Award  
http://www.onsfoundation.org/apply/ed/PatMcCue  
SPONSOR: Oncology Nursing Society (ONS), Oncology Nursing Society (ONS) Foundation